A maths career in pharma all adds up, says Source Health Economics

Mar 27, 2025

Written by Abby Paine and Jack Scerri

 

What better way to spend a Saturday morning than volunteering to lead an interactive mathematics workshop for a group of enthusiastic young students! That’s exactly what two of our staff did recently when they led a Royal Institution (Ri) Mathematics Masterclass for 50 students aged 13–14 years of age and attending local schools in the Maidenhead area.

Our colleagues, Abby Paine (statistician) and Jack Scerri (health economist) encouraged the students to consider how developing maths and science skills beyond school can open the door to a variety of rewarding careers, including those in medicine. Engaging with the students through a series of games and interactive examples, they demonstrated how statistics, probability, economic and ethical considerations have a fundamental part to play in decision making for health care systems around the world, including for the National Health Service (NHS) in the UK. Using the “Trolley problem” healthcare decision example, the students were encouraged to think through how we not only need ethics for decision making in healthcare, but also mathematics and economics to ensure we make fair decisions.

 

Many of the students were not previously aware that a career in the pharmaceutical industry is an option with qualifications in mathematics and/or economics. Abby and Jack were able to give an insight into some of the rewarding career opportunities available in helping new medicines become available to the people who need them most.

The RI Masterclasses are run by a dedicated team of volunteers, and are designed to encourage and inspire young people in the wide range of applications for mathematics, usually covering concepts that are not taught as part of a school curriculum.

 

If you would like to learn more about how advanced statistics is used to model treatment effects and healthcare costs, please contact Source Health Economics, a HEOR consultancy specialising in evidence generation, health economics, and communication.

More Insights

RAISE guidance – maintaining SLR standards in an AI-assisted future

RAISE guidance – maintaining SLR standards in an AI-assisted future

Written by Gwennie Ogilby (Associate Systematic Review Analyst) and Tom Metcalf (Senior Systematic Review Analyst)   Systematic literature reviews (SLRs) are considered one of the strongest forms of evidence to guide healthcare ... Read more

Thought Piece: How do we Reconcile Commoditisation and Strategic Value in Market Access?

Thought Piece: How do we Reconcile Commoditisation and Strategic Value in Market Access?

Written by Dan Spacie, CEO of SCIRIS   Executive Summary Market access services are undergoing a dual transformation. On one hand, technological advances and procurement pressures are driving commoditisation—standardising deliverables and ... Read more

Newborn genome screening: implications for health technology assessments of new orphan drugs

Newborn genome screening: implications for health technology assessments of new orphan drugs

Written by Luke Parkes   Introduction Newborn screening (NBS) is an impactful public health initiative that enables the diagnosis of severe conditions in asymptomatic infants at birth. Typically, NBS programmes include testing for a ... Read more

Navigating the complexities of economic evaluation for health technology assessment in dermatology

Navigating the complexities of economic evaluation for health technology assessment in dermatology

Written by Benjamin Clark   As the body’s largest organ, the skin is affected by a vast number of diseases, with over 3,000 distinct dermatological conditions impacting more than 1.8 billion individuals globally at any time (1). With ... Read more